In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ...

The drug didn’t show any superiority in the ... Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.

Cholinergic drugs (acetylcholine ... asthmatics and in COPD patients with a history of asthma, showing an additional bronchodilator effect on top of the current asthma treatment.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

A 4-month regimen recommended for drug-susceptible TB and 6-month regimen recommended for drug-resistant TB.

Currently used end points to assess drug efficacy for PAH may ... Early detection of PAH and referral to pulmonary hypertension centers for treatment will theoretically improve prognosis and ...

In terms of treatment for asthma and COPD ... With a bewildering number of new drugs available for asthma and COPD, HCPs are increasingly making their decisions based on the cost and the inhaler ...